
Neurocrine Biosciences is a drug manufacturers-specialty & generic business based in the US. Neurocrine Biosciences shares (NBIX) are listed on the NASDAQ and all prices are listed in US Dollars. Neurocrine Biosciences employs 1,300 staff and has a trailing 12-month revenue of around $1.6 billion.
How to buy Neurocrine Biosciences stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – NBIX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 in stock when you fund a new account within 30 days
eToro
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
tastytrade
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Neurocrine Biosciences stock price (NASDAQ: NBIX)
Use our graph to track the performance of NBIX stocks over time.Neurocrine Biosciences shares at a glance
Latest market close | $91.22 |
---|---|
52-week range | $88.38 - $129.29 |
50-day moving average | $98.99 |
200-day moving average | $107.48 |
Wall St. target price | $124.67 |
PE ratio | 144.7937 |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $0.63 |
Buy Neurocrine Biosciences stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Neurocrine Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Neurocrine Biosciences price performance over time
Historical closes compared with the close of $91.22 from 2023-05-26
1 week (2023-05-24) | -1.50% |
---|---|
1 month (2023-05-01) | -12.31% |
3 months (2023-03-03) | -9.84% |
6 months (2022-12-01) | -27.78% |
1 year (2022-05-27) | -2.02% |
---|---|
2 years (2021-05-28) | -5.20% |
3 years (2020-05-29) | 124.76 |
5 years (2018-05-31) | 96.26 |
Is Neurocrine Biosciences stock undervalued or overvalued?
Valuing Neurocrine Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neurocrine Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Neurocrine Biosciences financials
Revenue TTM | $1.6 billion |
---|---|
Operating margin TTM | 17.24% |
Gross profit TTM | $1 billion |
Return on assets TTM | 7.65% |
Return on equity TTM | 4.16% |
Profit margin | 4% |
Book value | $17.28 |
Market capitalisation | $8.9 billion |
TTM: trailing 12 months
Neurocrine Biosciences share dividends
We're not expecting Neurocrine Biosciences to pay a dividend over the next 12 months.
Neurocrine Biosciences share price volatility
Over the last 12 months, Neurocrine Biosciences's shares have ranged in value from as little as $88.38 up to $129.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurocrine Biosciences's is 0.4877. This would suggest that Neurocrine Biosciences's shares are less volatile than average (for this exchange).
Neurocrine Biosciences overview
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia.
Neurocrine Biosciences in the news
Are Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society 2023 Annual Congress
Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023
Frequently asked questions
What percentage of Neurocrine Biosciences is owned by insiders or institutions?Currently 1.06% of Neurocrine Biosciences shares are held by insiders and 95.257% by institutions. How many people work for Neurocrine Biosciences?
Latest data suggests 1,300 work at Neurocrine Biosciences. When does the fiscal year end for Neurocrine Biosciences?
Neurocrine Biosciences's fiscal year ends in December. Where is Neurocrine Biosciences based?
Neurocrine Biosciences's address is: 12780 El Camino Real, San Diego, CA, United States, 92130 What is Neurocrine Biosciences's ISIN number?
Neurocrine Biosciences's international securities identification number is: US64125C1099 What is Neurocrine Biosciences's CUSIP number?
Neurocrine Biosciences's Committee on Uniform Securities Identification Procedures number is: 64125C109
More guides on Finder
-
JP Morgan Personal Advisors review 2023
Access remote advice, planning and portfolio management from this established financial services company.
-
How to buy Energy Transfer Equity stock
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
-
How to buy Uranium Energy stock
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
-
How to buy Gold Royalty stock
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
-
Best apps and platforms for ETF investing
The best trading apps come with low fees and are easy to use.
-
What happens if a brokerage firm fails?
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
-
Best online brokers & platforms to buy gold stocks in May 2023
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
-
Silicon Valley Bank collapse: Which ETFs and stocks are impacted?
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
-
How to buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
-
SVB collapses: What does it mean for your portfolio?
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
Ask an Expert